For everyone, everywhere
OUR PERSPECTIVE
Shortcomings of existing therapies
Current standard of care treatments are ineffective for millions worldwide.
Significant burden
Affected People
Global population with mental health disorders
Of US population impacted
Expected that more than half of US population will have a mental health disorder at some point in their lifetime
Global economic impact
Estimated global economic costs of mental health disorders by 2030
Recent impact of COVID-19
Percentage of US adults experiencing symptoms of depression and anxiety rose from 11% in 2019 to 42% end of 2020
Urgent need for innovation
Respond inadequately
A third of patients with depression respond inadequately or relapse with current treatments within certain indications
Slow onset of treatment effect
Frontline treatments for depression and anxiety have slow onset (4-12w)
Relapse rate
Most of the patients treated for opioid use disorder (OUD) relapse
Psychiatry approvals since 2015
Only 17 new drugs approved by the FDA for psychiatry disorders since 2015 – less than 20% relative to oncology (N=107)
Our unique approach
Compounds with prior evidence in humans
To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.
Enabling platform technologies
Decentralized drug development
In addition to funding, our evolving companies have access to our deep domain expertise and operational backbone.
Learn more about our approach
OUR PROGRAMSWHERE WE’RE HEADED
Our technologies drive efficient drug discovery and improved treatment outcomes.
Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics.
OUR PROGRAMSNews & Insights
News
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation…
Articles
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson,…
Articles
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of…